z-logo
open-access-imgOpen Access
Candesartan in treating hypertension
Author(s) -
Л. О. Минушкина
Publication year - 2014
Publication title -
systemic hypertension
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg29003
Subject(s) - candesartan , medicine , pharmacokinetics , pharmacology , blood pressure , pharmacodynamics , angiotensin receptor , angiotensin ii , bioavailability , urology
Candesartan is a selective angiotensin II receptor blocker type 1. The distinctive features of its pharmacokinetics and pharmacodynamics are long duration of antihypertensive action, high selectivity and good bioavailability. In the treatment of hypertension, candesartan can effectively prevent morning rise in blood pressure. For preparation peculiar cerebro-and cardioprotective effects, the ability to reduce the risk of new cases of diabetes. The drug is effective in the treatment of nephropathy different genesis, including in patients with a marked reduction in renal function. Metabolic neutrality, the ability to prevent the development of micro-and macroangiopathy can recommend this angiotensin receptor blocker in the treatment of diabetic patients. Favorable profile of the pharmacokinetic properties of an advantage in efficacy of candesartan in comparison with other drugs of the same group.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom